Activity of ceftazidime-avibactam against clinical and isogenic laboratory Pseudomonas aeruginosa isolates expressing combinations of most relevant β-lactam resistance mechanisms

Gabriel Torrens, Gabriel Cabot*, Alain A. Ocampo-Sosa, M. Carmen Conejo, Laura Zamorano, Ferrán Navarro, Álvaro Pascual, Luis Martínez-Martínez, Antonio Oliver

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

32 Citations (Scopus)

Abstract

The activity of ceftazidime-avibactam was compared with that of ceftazidime alone and meropenem against a collection of 190 Pseudomonas aeruginosa clinical isolates recovered from a multicenter study of bloodstream infections. The addition of avibactam increased ceftazidime susceptibility in the complete collection of strains (64.7% to 91.1%) and particularly among subsets of isolates showing AmpC hyperproduction (10.9% to 76.1%) or multidrug resistance (MDR) profiles (27% to 77.8%). The MICs of ceftazidime-avibactam, in contrast with those of ceftazidime or meropenem, remained at ≤4 μg/ml for a panel of 16 P. aeruginosa PAO1 isogenic mutants expressing multiple combinations of the most relevant β-lactam resistance mechanisms.

Original languageEnglish
Pages (from-to)6407-6410
Number of pages4
JournalAntimicrobial Agents and Chemotherapy
Volume60
Issue number10
DOIs
Publication statusPublished - Oct 2016

Fingerprint

Dive into the research topics of 'Activity of ceftazidime-avibactam against clinical and isogenic laboratory Pseudomonas aeruginosa isolates expressing combinations of most relevant β-lactam resistance mechanisms'. Together they form a unique fingerprint.

Cite this